CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionOperating margin is 94.4%, higher than 95% of its Biotechnology peers (median -34.2%)
- FinancialsAltman Z-Score 10.82: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
936.33MUSDvs all stocks (USD)
Trailing P/E
5.49xvs Biotechnology peers
Revenue (TTM)
191.44MUSDvs all stocks (USD)
Profit Margin
83.95%vs Biotechnology peers
Beta
0.6180xvs all stocks
52-Week Change
49.04%vs all stocks
Market Capitalization
936.33MUSDvs all stocks (USD)
Enterprise Value
819.33MUSDvs all stocks (USD)
Trailing P/E
5.49xvs Biotechnology peers
Forward P/E
-27.59xvs Biotechnology peers
PEG Ratio
-0.0071xvs Biotechnology peers
Price to Sales (TTM)
4.71xvs Biotechnology peers
Price to Book (MRQ)
3.45xvs Biotechnology peers
Enterprise to Revenue
4.28xvs Biotechnology peers
Enterprise to EBITDA
5.28xvs Biotechnology peers
Profit Margin
83.95%vs Biotechnology peers
Operating Margin
94.41%vs Biotechnology peers
Return on Assets (TTM)
49.18%vs Biotechnology peers
Return on Equity (TTM)
94.73%vs Biotechnology peers
Revenue (TTM)
191.44MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.9950USDUpdated Jul 17, 2026Quarterly Revenue Growth
10054.50%vs Biotechnology peers
Gross Profit (TTM)
171.04MUSDvs all stocks (USD)
EBITDA (TTM)
155.14MUSDvs all stocks (USD)
Net Income (TTM)
160.72MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
10054.54%vs Biotechnology peers
Operating Cash Flow (TTM)
-34.36MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-90.41MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
14.08MUSDFY2025 · Dec 31, 2025Operating Income
-27.05MUSDvs all stocks (USD)
Pre-tax Income
-33.50MUSDFY2025 · Dec 31, 2025Net Income
-33.50MUSDFY2025 · Dec 31, 2025EBIT
-33.40MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-22.62MUSDFY2025 · Dec 31, 2025Research & Development
25.24MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
15.89MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.07MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
97.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.1700USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.1700USDFY2025 · Dec 31, 2025Basic Shares Outstanding
191.60MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
191.60MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-33.50MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-39.02MUSDFY2025 · Dec 31, 2025Free Cash Flow
-39.38MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
18.01MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-33.50MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
363.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.95MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-3.22MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.38MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.99MUSDFY2025 · Dec 31, 2025Capital Expenditures
364.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-140.06MUSDFY2025 · Dec 31, 2025Sale of Investments
155.28MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
15.58MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
196.95MSharesUpdated Jul 17, 2026Float Shares
121.37MSharesUpdated Jul 17, 2026Shares Short
17.11MSharesUpdated Jul 17, 2026Short Ratio
7.29daysvs all stocks
Short % of Shares Outstanding
12.89%vs all stocks
% Held by Insiders
20.46%vs all stocks
% Held by Institutions
71.92%vs all stocks
Total Cash (MRQ)
95.23MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4820USDUpdated Jul 17, 2026Total Debt (MRQ)
3.91MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0150xvs Biotechnology peers
Current Ratio (MRQ)
54.26xvs Biotechnology peers
Book Value per Share (MRQ)
1.32USDUpdated Jul 17, 2026Total Assets
94.62MUSDvs all stocks (USD)
Total Current Assets
94.46MUSDFY2025 · Dec 31, 2025Total Liabilities
18.04MUSDFY2025 · Dec 31, 2025Total Non-current Assets
162.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
12.04MUSDFY2025 · Dec 31, 2025Total Current Liabilities
6.01MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
18.01MUSDFY2025 · Dec 31, 2025Other Short-term Investments
73.46MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.45MUSDFY2025 · Dec 31, 2025Accounts Payable
1.17MUSDFY2025 · Dec 31, 2025Short-term Debt
547.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
640.00KUSDFY2025 · Dec 31, 2025Long-term Debt
199.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
11.84MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.42BUSDFY2025 · Dec 31, 2025Retained Earnings
-1.38BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
76.58MUSDvs all stocks (USD)
52-Week Low
3.08USDUpdated Jul 17, 202652-Week High
5.38USDUpdated Jul 17, 202652-Week Change
49.04%vs all stocks
Beta
0.6180xvs all stocks
50-Day MA
4.49USDUpdated Jul 17, 2026200-Day MA
4.44USDUpdated Jul 17, 2026Avg 10-Day Volume
2.77MSharesUpdated Jul 17, 2026Avg 30-Day Volume
2.54MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
0.8300USDUpdated Jul 17, 2026Other Income / Expense
-10.42MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 94.4%, higher than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: 0.94Industry median: -0.34Industry P95: 0.41Peers compared: 261
Profit margin is 84%, higher than 95% of its Biotechnology peers (median -45.7%)Significant
Profit margin: 0.84Industry median: -0.46Industry P95: 0.43Peers compared: 261
Return on equity is 94.7%, higher than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: 0.95Industry median: -0.22Industry P95: 0.23Peers compared: 261
Return on assets is 49.2%, higher than 95% of its Biotechnology peers (median -20.1%)Significant
Return on assets: 0.49Industry median: -0.20Industry P95: 0.15Peers compared: 261
Current ratio is 54.26×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 54.26Industry median: 5.64Industry P95: 23.02Peers compared: 261
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 160,720,000Operating Cash Flow (USD, TTM): -34,356,000
Financial Health
Altman Z-Score 10.82: safe zoneNotable
Altman Z-Score: 10.82
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Guizhou Bailing Group Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Geron Corporation
Tier 1ProductionApproval-Gated PipelineRule
Beijing Tong Ren Tang Chinese Medicine Company Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing SL Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jiudian Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Annexon, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pharma Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
L&C Bio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Nanjing Xinjiekou Department Store Co. Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Halo Microelectronics Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Olaplex Holdings, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity